Deep-dive briefing

Fri · 4 Sep 2026

A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.

Phase 2 Evidence and Impact Analysis

Given the large batch (119 articles), I focus Phase 2 scoring on all articles but provide detailed commentary on the highest-impact items, with abbreviated treatment of lower-tier entries.

Phase 2 Scored Articles

Scoring notes applied batch-wide:

All abstract-only access articles: Evidence Strength capped ≤6 unless multicenter cohort or meta-analysis with sufficient metadata
Non-human studies: Clinical Relevance ≤5
Low classification_confidence: conservative reduction applied
Reviews and editorials: Evidence Strength ≤4 unless synthesizing RCT-level data

Article 1 — Aluri & Kishtagari: Closing the disease modification gap in myelofibrosis (PMID 42692917)

Dimension	Score	Rationale
Scientific Novelty	7	Synthesizes next-gen therapies beyond JAK inhibition; conceptually important framing
Clinical Relevance	6	Directly relevant to MPN clinicians but no new trial data
Population Reach	4	MPN rare (~3–5/100k); meaningful within heme-onc specialty
Implementation Speed	2	Narrative review; no deployable tool or therapy
Evidence Strength	3	Expert review, no original data

Key quantitative result: None reported (narrative review)
External validation: N/A
Main limitation: Opinion-based; does not present original clinical data
Equity implications: Access to clinical trials inequitably distributed; rural/low-income patients least likely to benefit
Evidence Maturity (revised): Exploratory ✓
Original triage_score: 8 | Phase 2 composite: 4.9

Article 2 — Nakayama et al.: UK MRP risk profile in transplant-ineligible myeloma (PMID 42692463)

Dimension	Score	Rationale
Scientific Novelty	6	External validation of existing UK prognostic tool in Japanese cohort
Clinical Relevance	6	Risk stratification directly informs treatment selection
Population Reach	5	Multiple myeloma ~7/100k; transplant-ineligible subset is large
Implementation Speed	5	Tool uses routine parameters; implementable if validated broadly
Evidence Strength	5	Cohort study; abstract only; unclear sample size

Key quantitative result: Not reported in available abstract
External validation: Cross-national validation attempt (UK model in Japan) — valuable but limited by abstract access
Main limitation: Abstract only; sample size unknown; anti-CD38 era applicability not yet confirmed
Equity implications: Japanese-specific cohort; generalizability unclear across other Asian and non-Asian populations
Evidence Maturity (revised): Validated (partially) — upgrade conditional on full-text
Original triage_score: 8 | Phase 2 composite: 5.5

Article 3 — Ferreira et al.: Genetic spectrum of parkinsonism in Brazil (PMID 42691865)

Dimension	Score	Rationale
Scientific Novelty	6	First or rare characterization of PD genetics in admixed Brazilian population
Clinical Relevance	5	Informs diagnostic workup but no immediate treatment change
Population Reach	5	~215M Brazilians; parkinsonism prevalence ~1–2% in elderly
Implementation Speed	3	Requires infrastructure for NGS; equity barriers high
Evidence Strength	5	Cohort study; abstract only; sample size unknown

Key quantitative result: Not specified in available abstract
External validation: Not reported
Main limitation: Admixed population underrepresented in genomic databases; variant classification uncertain
Equity implications: Directly addresses one of the world's most genetically diverse and research-underserved populations; high equity value
Evidence Maturity (revised): Exploratory (not Validated — mismatch with Phase 1 classification)
Original triage_score: 8 | Phase 2 composite: 4.7

Article 4 — Chang et al.: ML in epilepsy management — systematic review & meta-analysis (PMID 42692952) — Lancet Digital Health

Dimension	Score	Rationale
Scientific Novelty	6	Systematic synthesis of ML in epilepsy; field is active but not yet mature
Clinical Relevance	7	Treatment selection in epilepsy is chronically trial-and-error; ML support is high-value problem
Population Reach	8	~70M people with epilepsy worldwide
Implementation Speed	3	Clinical integration of ML decision support requires infrastructure, regulatory approval
Evidence Strength	5	Systematic review in Lancet Digital Health — high-prestige venue; but study design labeled "RCT (inferred)" which is almost certainly a misclassification of a systematic review

Key quantitative result: Not extractable from abstract
External validation: Meta-analysis design inherently synthesizes across studies
Main limitation: Abstract only; study design misclassified; applicability of ML models across diverse epilepsy populations unclear; many included models likely not externally validated
Equity implications: Epilepsy disproportionately affects low/middle-income countries where ML tools are least accessible
Evidence Maturity (revised): Exploratory (not Practice-Changing — meta-analysis of heterogeneous ML studies without clinical outcome evidence)
Original triage_score: 8 | Phase 2 composite: 5.9

Article 5 — Yu et al.: Spatial habitat radiomics predicts TLS status in breast cancer (PMID 42692536)

Dimension	Score	Rationale
Scientific Novelty	7	Non-invasive TLS assessment via radiomics + IDO1+ migratory DC axis is conceptually novel
Clinical Relevance	6	Patient stratification for immunotherapy; no immediate practice change without prospective validation
Population Reach	7	Breast cancer ~2.3M new cases/year globally
Implementation Speed	4	Requires radiomics infrastructure; not routine
Evidence Strength	5	Cohort/observational; abstract only; multicenter unclear

Key quantitative result: Not extractable from abstract
External validation: Not confirmed
Main limitation: Retrospective cohort; abstract only; spatial radiomics requires specialized platforms
Equity implications: Breast cancer disproportionately diagnosed late in LMICs; radiomics infrastructure gap is significant
Evidence Maturity (revised): Exploratory (not Validated — no prospective confirmation)
Original triage_score: 8 | Phase 2 composite: 5.8

Article 6 — Gurpinar et al.: Instrumentation failure in dynamic vs. rigid spinal stabilization (PMID 42690488)

Dimension	Score	Rationale
Scientific Novelty	4	Incrementally adds to existing propensity-matched spine literature
Clinical Relevance	5	Surgeons selecting construct type; moderate direct impact
Population Reach	6	Degenerative spine disease is one of most common surgical indications globally
Implementation Speed	5	Comparative data directly usable by surgeons
Evidence Strength	5	Propensity-matched cohort (n=952); observational; no causation

Key quantitative result: Not specified in abstract
Main limitation: Residual confounding; observational; single or limited center
Equity implications: Spinal surgery access highly unequal globally; less relevant to low-resource settings
Evidence Maturity (revised): Validated (associative only) ✓
Original triage_score: 8 | Phase 2 composite: 5.0

Article 7 — Gong et al.: Oral aging and systemic aging (PMID 42688549)

Dimension	Score	Rationale
Scientific Novelty	4	Review synthesizes known mechanisms; oral-systemic aging link not new
Clinical Relevance	4	Conceptual framework; no direct clinical tool
Population Reach	7	Universal aging relevance
Implementation Speed	1	Far from clinical translation
Evidence Strength	2	Narrative review; mixed species; Chinese-language journal

Evidence Maturity (revised): Exploratory ✓
Original triage_score: 8 | Phase 2 composite: 4.0

Article 8 — He et al.: Oral microbiota in age-related homeostatic dysregulation (PMID 42688523)

Dimension	Score	Rationale
Scientific Novelty	5	Oral microbiome-aging link is growing area; this is a review
Clinical Relevance	3	No actionable clinical tool yet
Population Reach	7	Universal aging relevance
Implementation Speed	1	Early-stage mechanistic review
Evidence Strength	2	Narrative review only

Evidence Maturity (revised): Exploratory ✓
Original triage_score: 8 | Phase 2 composite: 3.7

Article 9 — Sun et al.: Anti-inflammatory diet, physical activity, and all-cause mortality in Chinese older adults (PMID 42688224)

Dimension	Score	Rationale
Scientific Novelty	5	First prospective cohort in Chinese elderly; geographic novelty
Clinical Relevance	6	Actionable lifestyle messaging; informs public health
Population Reach	8	Large elderly Chinese population; global applicability of diet+PA findings
Implementation Speed	7	Diet and activity interventions are immediately actionable
Evidence Strength	5	Prospective cohort design (design label unclear); abstract only

Key quantitative result: Not reported in abstract
Main limitation: Observational; confounding likely; Chinese-specific dietary patterns may limit generalizability
Equity implications: Chinese-specific; findings may not apply to other ethnic groups without validation
Evidence Maturity (revised): Exploratory ✓
Original triage_score: 8 | Phase 2 composite: 6.3

Article 10 — Bührman et al.: Multi-stakeholder governance for iPSC drug repurposing in rare diseases (PMID 42692009)

Dimension	Score	Rationale
Scientific Novelty	5	Policy/governance framework is important but not scientifically novel
Clinical Relevance	4	Indirect; enables future research infrastructure
Population Reach	6	Rare disease community broadly (~300M people worldwide with rare diseases)
Implementation Speed	3	Governance reform is slow
Evidence Strength	2	Commentary/opinion piece

Evidence Maturity (revised): Exploratory ✓
Original triage_score: 8 | Phase 2 composite: 4.3

Article 11 — Li et al.: LLMs for NMOSD patient education (PMID 42688174)

Dimension	Score	Rationale
Scientific Novelty	5	LLM evaluation for rare disease education; growing area
Clinical Relevance	6	Real-world patient interaction data; directly informs which LLMs to deploy
Population Reach	4	NMOSD is rare (~4/100k); equity value is high given limited specialist access
Implementation Speed	7	LLM tools are already deployed; model selection guidance is immediately actionable
Evidence Strength	5	Cohort/observational with real patient interactions; abstract only

Key quantitative result: Not specified
Main limitation: Short study window (Mar–Apr 2026); patient satisfaction is subjective; clinician role remains essential
Equity implications: Rare disease patients in underserved areas with no specialist access benefit most
Evidence Maturity (revised): Validated ✓
Original triage_score: 8 | Phase 2 composite: 5.5

Article 12 — Sun et al.: Tongmai Yangxin Pills in I/R arrhythmia (rat model) (PMID 42693062)

Non-human/mixed model; AGE-RAGE pathway; TCM study
Clinical Relevance ≤5 (non-human)
Evidence Maturity (revised): Exploratory ✓
Original triage_score: 7 | Phase 2 composite: 3.5

Article 13 — Voznyy et al.: Intranasal dexmedetomidine — systematic review & meta-analysis (PMID 42692256)

Dimension	Score	Rationale
Scientific Novelty	4	Dexmedetomidine for premedication is established; intranasal route is a refinement
Clinical Relevance	6	Anesthesia practice directly applicable
Population Reach	7	Any adult undergoing general anesthesia
Implementation Speed	5	Intranasal route is already used; meta-analysis informs best practice
Evidence Strength	4	Systematic review of RCTs; certainty rated low/very low for many outcomes

Evidence Maturity (revised): Exploratory ✓ (low certainty)
Original triage_score: 7 | Phase 2 composite: 5.4

Article 14 — Büchler et al.: MCED tests — overview of technologies and clinical evidence (PMID 42692838) 🔴

Dimension	Score	Rationale
Scientific Novelty	5	Review of existing MCED landscape; not original data
Clinical Relevance	7	MCED is among the most consequential near-term cancer screening innovations
Population Reach	9	Pan-cancer screening; potentially affects every adult in screening-eligible ages
Implementation Speed	4	Requires health-economic validation and pathway standardization
Evidence Strength	4	Review article; abstract only

Main limitation: Reviews existing evidence without adding new data; health economics gap is explicitly noted
Equity implications: MCED most likely to benefit affluent populations first; access disparities are a major concern
Evidence Maturity (revised): Exploratory ✓
Original triage_score: 7 | Phase 2 composite: 6.3

Article 15 — Xue et al.: Novel blood-based tests for CRC screening (PMID 42692772) 🔴

Dimension	Score	Rationale
Scientific Novelty	6	Three validated blood-based CRC tests reviewed (Epi proColon, Shield, Freenome)
Clinical Relevance	7	CRC screening compliance is a major public health problem; blood tests improve uptake
Population Reach	9	CRC is #2 cancer killer in US; screening-age population is massive
Implementation Speed	6	Tests already approved/in trials; review informs adoption
Evidence Strength	4	Review article; abstract only

Main limitation: Low sensitivity for advanced precancerous lesions; low follow-up colonoscopy rates after positive test
Equity implications: Blood-based testing may improve screening in populations with lower colonoscopy access; but cost remains a barrier
Evidence Maturity (revised): Exploratory ✓ (despite validated tests — evidence synthesis itself is review-level)
Original triage_score: 7 | Phase 2 composite: 6.7

Article 16 — Asombang et al.: CRC screening with colonoscopy (PMID 42692771)

Dimension	Score	Rationale
Scientific Novelty	4	AI/robotics enhancement of colonoscopy is incremental
Clinical Relevance	7	Colonoscopy remains gold standard; review directly informs practice
Population Reach	9	Universal CRC screening relevance
Implementation Speed	5	AI colonoscopy tools exist but not universally deployed
Evidence Strength	4	Review; abstract only

Evidence Maturity (revised): Exploratory ✓
Original triage_score: 7 | Phase 2 composite: 6.3

Article 17 — Gamage et al.: Weight management for young adults in Sri Lanka — qualitative (PMID 42692514)

Qualitative study; limited generalizability; misclassified into early cancer detection topic
Original triage_score: 7 | Phase 2 composite: 3.2

Article 18 — Chang et al.: Cataract surgery and diabetic retinopathy — 11-year cohort (PMID 42692501)

Dimension	Score	Rationale
Scientific Novelty	5	Association between cataract surgery and DR progression is underexplored
Clinical Relevance	6	Informs post-cataract DR surveillance protocols
Population Reach	7	~500M people with diabetes globally; many undergo cataract surgery
Implementation Speed	6	Could modify screening intervals post-surgery without new infrastructure
Evidence Strength	5	Population-based 11-year retrospective cohort; large denominator inferred

Equity implications: Diabetic retinopathy disproportionately affects lower-income populations with less access to follow-up
Evidence Maturity (revised): Validated ✓
Original triage_score: 7 | Phase 2 composite: 5.9

Article 19 — Vauclin et al.: AI models vs. ASES Neer Circle Delphi for rotator cuff recommendations (PMID 42692242)

Dimension	Score	Rationale
Scientific Novelty	5	LLM benchmarking in orthopedics is emerging
Clinical Relevance	5	Adjunctive decision support; not replacing surgeons
Population Reach	5	Rotator cuff tears common in aging population
Implementation Speed	5	LLMs already accessible; integration is modest barrier
Evidence Strength	4	Computer modeling study; not patient outcomes

Evidence Maturity (revised): Exploratory (not Practice-Changing)
Original triage_score: 7 | Phase 2 composite: 4.9

Article 20 — Danilatou & Arachchillage: AI replacing traditional scores in thrombosis — ethical obligations (PMID 42692078)

Dimension	Score	Rationale
Scientific Novelty	5	Important governance framing; not novel empirically
Clinical Relevance	6	Directly relevant to clinicians implementing AI risk scores
Population Reach	7	Thrombosis/VTE affects millions annually
Implementation Speed	5	Governance frameworks can be deployed relatively quickly
Evidence Strength	2	Expert commentary

Evidence Maturity (revised): Exploratory ✓
Original triage_score: 7 | Phase 2 composite: 5.4

Article 21 — Pezzuto et al.: AI-based tumor bed stroma assessment in NSCLC after neoadjuvant therapy (PMID 42691847)

Dimension	Score	Rationale
Scientific Novelty	6	AI fibrosis quantification in post-neoadjuvant NSCLC is novel and multitherapy comparative
Clinical Relevance	6	Refines post-surgical risk stratification; could influence adjuvant decisions
Population Reach	7	NSCLC is the leading cancer killer globally
Implementation Speed	4	Requires AI pathology platforms; not routine
Evidence Strength	5	Multicenter cohort (implied); abstract only

Equity implications: Pathology AI least available in LMICs where NSCLC burden is rising
Evidence Maturity (revised): Validated ✓
Original triage_score: 7 | Phase 2 composite: 5.8

Article 22 — Kubota et al.: ECV fraction and tumor fibrosis as biomarkers in tongue SCC (PMID 42692963)

Dimension	Score	Rationale
Scientific Novelty	6	ECV-derived imaging biomarker for CAF characterization in head/neck cancer is novel
Clinical Relevance	6	Non-invasive guidance for elective neck dissection decisions
Population Reach	5	Tongue SCC moderate incidence; rising globally
Implementation Speed	5	CECT is standard; ECV calculation adds minimal workflow
Evidence Strength	4	Single-center cohort; abstract only; small implied sample

Evidence Maturity (revised): Exploratory (not Validated — needs multicenter confirmation)
Original triage_score: 7 | Phase 2 composite: 5.4

Article 23 — Chen et al.: KRAS expression + genomic profiling in gastric cancer (PMID 42692168)

Dimension	Score	Rationale
Scientific Novelty	6	Expression-based stratification complementing genomic profiling is conceptually relevant
Clinical Relevance	6	~50% GC with RAS pathway alterations; better patient selection is high-value
Population Reach	6	Gastric cancer ~1M new cases/year globally
Implementation Speed	4	Requires integration of expression and genomic platforms
Evidence Strength	4	Design labeled "meta-analysis (inferred)" — suspect; abstract only

Evidence Maturity (revised): Potentially Practice-Changing (conditional on full data — maintain with caution)
Original triage_score: 7 | Phase 2 composite: 5.4

Article 24 — Mannucci et al.: Germline multigene panel testing for CRC — systematic review & meta-analysis (PMID 42692037) — Lancet Gastroenterology

Dimension	Score	Rationale
Scientific Novelty	6	Quantifies diagnostic yield of multigene germline panels in CRC — fills key evidence gap
Clinical Relevance	7	Directly informs guideline decisions about germline testing
Population Reach	8	CRC is highly prevalent; hereditary fraction ~5–10% of all cases
Implementation Speed	5	Germline testing is available; guideline uptake takes 2–5 years
Evidence Strength	6	Systematic review/meta-analysis in Lancet GH; high-quality synthesis venue

Key quantitative result: Diagnostic yield of multigene panel testing — not specified in abstract
Main limitation: Abstract only; yield varies by testing strategy (all-comers vs. Lynch/high-risk)
Equity implications: Germline testing access is highly unequal; greatest unmet need in underinsured populations
Evidence Maturity (revised): Potentially Practice-Changing ✓ (Lancet journal; meta-analysis design)
Original triage_score: 7 | Phase 2 composite: 6.5

Article 25 — Li et al.: Real-world belzutifan in sporadic metastatic RCC (PMID 42692967)

Dimension	Score	Rationale
Scientific Novelty	5	Real-world data confirming trial outcomes in broader/sicker population
Clinical Relevance	7	Confirms applicability in heavily pretreated patients with visceral mets not in trials
Population Reach	5	mRCC niche but approved indication
Implementation Speed	7	Belzutifan is FDA-approved; real-world data immediately inform prescribing
Evidence Strength	5	Multicenter retrospective cohort; abstract only; diverse patient population

Key quantitative result: "Consistent clinical outcomes and toxicity profile with prior reports" — specific ORR/PFS not extractable
Equity implications: Diverse, heavily pretreated cohort included — positive for generalizability
Evidence Maturity (revised): Validated ✓
Original triage_score: 7 | Phase 2 composite: 5.9

Article 26 — Wu et al.: Preoperative TACE + lenvatinib + PD-1 inhibitors in resectable HCC (PMID 42691921)

Dimension	Score	Rationale
Scientific Novelty	6	Triple neoadjuvant combination in resectable HCC stages Ib–IIIa is novel
Clinical Relevance	7	High recurrence after HCC surgery is a major unmet need; neoadjuvant approach is promising
Population Reach	6	HCC ~900k new cases/year globally; China carries heavy burden
Implementation Speed	4	Propensity-matched cohort data; not guideline-ready
Evidence Strength	5	Multicenter propensity-matched cohort; abstract only

Main limitation: Retrospective; residual confounding; Chinese healthcare system specific
Equity implications: HCC disproportionately affects low/middle-income countries (viral hepatitis endemic regions)
Evidence Maturity (revised): Validated ✓ (associatively, not causally)
Original triage_score: 7 | Phase 2 composite: 5.9

Article 27 — Patel et al.: Osteoarthritis as whole-joint disease, Part I (PMID 42692563)

Review of current OA standard of care; clinical relevance for a very prevalent condition
Original triage_score: 7 | Phase 2 composite: 4.3

Article 28 — Cui & Du: Gut-IVD axis and microbiome-driven disc degeneration (PMID 42691205)

Review; mechanistic framework for IDD; no clinical data
Original triage_score: 7 | Phase 2 composite: 3.6

Article 29 — He et al.: DNA methylation in aging-related bone metabolism (PMID 42688583)

Mixed-species review; epigenetic clocks and osteoporosis; early stage
Original triage_score: 7 | Phase 2 composite: 3.5

Article 30 — Lu: AI-augmented evidence in rare disease drug development (PMID 42692189) 🟡

Dimension	Score	Rationale
Scientific Novelty	6	"Snapshots to 360-degree movies" framework is conceptually interesting
Clinical Relevance	5	Regulatory/HTA methodology; indirect clinical impact
Population Reach	7	Rare disease community broadly (~300M worldwide)
Implementation Speed	3	Methodological framework; adoption requires industry and regulator buy-in
Evidence Strength	2	Single-author opinion piece

Evidence Maturity (revised): Exploratory ✓
Original triage_score: 7 | Phase 2 composite: 4.7

Article 31 — Cortelli et al.: Ki-67 and invasion patterns identify high-risk pNETs (PMID 42690303) 🟡

Dimension	Score	Rationale
Scientific Novelty	5	Challenges size-only paradigm for pNET risk; important but not new in principle
Clinical Relevance	7	Directly informs surgical decision-making for pNETs
Population Reach	3	pNETs rare (~1/100k); but high unmet need
Implementation Speed	6	Ki-67 and invasion already assessed routinely; risk model integration is feasible
Evidence Strength	4	Unspecified design; abstract only; Brazilian single-center implied

Equity implications: Brazil-specific; pNETs globally underdiagnosed in LMICs
Evidence Maturity (revised): Exploratory ✓
Original triage_score: 7 | Phase 2 composite: 5.2

Article 32 — Ichimasa et al.: AI-driven decision-making after ER for early gastric cancer (PMID 42692980) 🟢

Dimension	Score	Rationale
Scientific Novelty	6	AI integration for post-ER decision-making to avoid over-treatment is genuinely important
Clinical Relevance	7	~90% of post-ER gastrectomies are unnecessary based on current data; AI could prevent harm
Population Reach	6	Early gastric cancer predominantly East Asian; rising in other regions
Implementation Speed	4	Requires AI validation in prospective trials before deployment
Evidence Strength	3	Review only; abstract only

Evidence Maturity (revised): Exploratory ✓ (not Practice-Changing as labeled — no prospective AI outcomes data)
Original triage_score: 7 | Phase 2 composite: 5.5

Article 33 — Owen et al.: Fixed duration CLL therapy in Canada — observational (PMID 42692910)

Real-world Canadian CLL data; limited novel content; outcome details absent
Original triage_score: 6 | Phase 2 composite: 4.2

Article 34 — Batra et al.: ALK IHC positivity in high-grade pulmonary NEC (PMID 42692813)

Dimension	Score	Rationale
Scientific Novelty	6	IHC-genomic discordance in pulmonary NEC with ALK — clinically important diagnostic pitfall
Clinical Relevance	7	Prevents misuse of ALK-targeted therapy in a non-eligible indication
Population Reach	4	High-grade pulmonary NEC is rare
Implementation Speed	6	Recommends RNA-seq before ALK therapy — actionable
Evidence Strength	5	Cohort; abstract only

Evidence Maturity (revised): Validated ✓
Original triage_score: 6 | Phase 2 composite: 5.7

Articles 35–36 — Preference signaling in surgery residency match (PMID 42691946); Paratonia CAP pilot (PMID 42691807)

Medical education and geriatrics respectively; outside core clinical pipeline topics
Phase 2 composites: 3.2, 3.8

Article 37 — Mirzaei et al.: HbD co-inheritance with thalassemia — 202 patients (PMID 42687585)

Dimension	Score	Rationale
Scientific Novelty	5	Characterizes HbD-Punjab CBC patterns in a reasonably sized cohort
Clinical Relevance	6	Directly informs CBC interpretation in HbD carriers
Population Reach	5	HbD Punjab prevalent in Iran, India, Pakistan — significant regional burden
Implementation Speed	6	CBC-based; no new infrastructure required
Evidence Strength	5	Retrospective comparative cohort; n=202; molecularly confirmed

Equity implications: South Asian and Middle Eastern populations are most affected; often underrepresented in hematology guidelines
Evidence Maturity (revised): Validated ✓
Original triage_score: 6 | Phase 2 composite: 5.5

Article 38 — Li et al.: CBC-derived inflammatory biomarkers in neonatal cholestasis (PMID 42686933)

Dimension	Score	Rationale
Scientific Novelty	5	CBC markers for neonatal cholestasis risk — novel application
Clinical Relevance	5	Preterm infants; potential early marker but causality not established
Population Reach	5	Preterm births are common globally; cholestasis affects significant subset
Implementation Speed	6	CBC is routine; low implementation barrier
Evidence Strength	5	Matched case-control; abstract only

Evidence Maturity (revised): Validated (associative) ✓
Original triage_score: 6 | Phase 2 composite: 5.2

Article 39 — Budinská: Microbiome as biomarker for early cancer detection (PMID 42692847) 🔴

Exploratory review; microbiome-cancer detection still pre-clinical; abstract only
Original triage_score: 6 | Phase 2 composite: 4.0

Article 40 — Mišove et al.: Polygenic risk score in cancer susceptibility (PMID 42692837) 🔴

Review; PRS in cancer well-established topic; limited transferability discussed
Original triage_score: 6 | Phase 2 composite: 3.9

Article 41 — White et al.: CRC screening adherence in underserved populations (PMID 42692779) 🔴

Dimension	Score	Rationale
Scientific Novelty	4	Barriers to CRC screening in underserved populations well-documented
Clinical Relevance	7	High equity value; closing screening gaps has direct mortality impact
Population Reach	8	Underserved populations globally; large US burden
Implementation Speed	6	Many strategies described are deployable now
Evidence Strength	3	Review only

Evidence Maturity (revised): Exploratory ✓
Original triage_score: 6 | Phase 2 composite: 5.7

Articles 42–45 — CRC screening quality program (PMID 42692778), Agentic AI in radiology (PMID 42692874), Deep learning for vertebral fracture (PMID 42692873), NLP for endoscopy AEs (PMID 42692516)

All reviews or single-center cohorts; incremental contributions to AI diagnostics
Phase 2 composites: 3.8, 4.2, 4.8, 4.9

Article 46 — Schmidt et al.: ACR Imaging AI Registry — LLM monitoring (PMID 42692226)

Dimension	Score	Rationale
Scientific Novelty	6	First national imaging AI registry with LLM-based performance extraction is notable infrastructure
Clinical Relevance	6	Enables scalable AI monitoring — addresses a real deployment gap
Population Reach	7	Radiology AI deployed nationally affects all imaging patients
Implementation Speed	6	Registry already operational
Evidence Strength	5	Descriptive cohort of registry workflow; not a clinical outcome study

Evidence Maturity (revised): Validated ✓
Original triage_score: 6 | Phase 2 composite: 6.1

Article 47 — Hendra Raman & Somasundaram: Explainability in hospital readmission ML (PMID 42691955)

Methodological ML paper using public dataset; no clinical deployment
Original triage_score: 6 | Phase 2 composite: 3.5

Article 48 — Joghataee et al.: ML for rare fungal and TB infections in hospitalized patients (PMID 42691871)

Dimension	Score	Rationale
Scientific Novelty	6	ML for detecting rare/atypical pathogens is underexplored
Clinical Relevance	6	Early identification of fungal/TB infections reduces mortality
Population Reach	6	Hospitalized immunocompromised patients globally
Implementation Speed	4	Needs external validation and prospective trials
Evidence Strength	5	Cohort study; abstract only; single center implied

Evidence Maturity (revised): Validated ✓ (internal validation only)
Original triage_score: 6 | Phase 2 composite: 5.4

Articles 49–51 — Agentic AI in dentistry (PMID 42691769), miR-1289 in GBM (PMID 42692382), Host metabolomics/REE in cancer cachexia (PMID 42692361)

Early-stage/preclinical or opinion pieces; limited near-term clinical impact
Phase 2 composites: 3.2, 3.8, 4.0

Article 52 — Li: CRISPR/Cas9 multiplex ctDNA/miRNA sensing platform (PMID 42692324) 🔴

Preclinical (mixed species); novel technology but very early stage
Original triage_score: 6 | Phase 2 composite: 3.2

Article 53 — Vinciguerra & Tsoneva: Extracellular chromatin fragments as cancer biomarkers (PMID 42692176) 🔴

Mixed-species review; cfDNA + histone biomarker synthesis; early stage
Original triage_score: 6 | Phase 2 composite: 3.8

Article 54 — Tabár et al.: Neoduct dedifferentiation and breast cancer-specific survival (PMID 42691750)

Dimension	Score	Rationale
Scientific Novelty	6	Imaging biomarker linked to tumor origin site and survival — conceptually important
Clinical Relevance	5	Informs diagnostic re-evaluation but no immediate management change
Population Reach	7	Breast cancer universal relevance
Implementation Speed	4	Requires integration of mammogram calcification pattern with histopathology
Evidence Strength	5	Cohort; abstract only; long-term follow-up implied

Evidence Maturity (revised): Validated ✓
Original triage_score: 6 | Phase 2 composite: 5.4

Article 55 — Mathews et al.: Real-world belzutifan in sporadic ccRCC with genomic correlation (PMID 42692965)

Dimension	Score	Rationale
Scientific Novelty	6	Genomic correlate attempt in real-world belzutifan is novel
Clinical Relevance	6	Confirms efficacy; genomic underpowered but directionally interesting
Population Reach	4	ccRCC niche
Implementation Speed	7	Approved drug; real-world data directly actionable
Evidence Strength	5	Retrospective cohort; abstract only

Evidence Maturity (revised): Validated ✓
Original triage_score: 6 | Phase 2 composite: 5.7

Article 56 — [Wu et al.: Preoperative TACE + lenvatinib + PD-1 in HCC] — Already covered as Article 26

Article 57 — cGAMP-liposome STING agonist adjuvant (PMID 42692376)

Mixed-species preclinical; 37-fold lower EC50 for STING activation; interesting early data; Clinical Relevance ≤5
Original triage_score: 6 | Phase 2 composite: 3.0

Article 58 — Wei et al.: DIPG/DMG H3 K27-altered — comprehensive review (PMID 42692100)

Dimension	Score	Rationale
Scientific Novelty	5	Comprehensive DIPG review through July 2026; up-to-date synthesis
Clinical Relevance	6	Pediatric lethal brainstem tumor with ~11-month median OS; high unmet need
Population Reach	3	Rare pediatric cancer; but devastating
Implementation Speed	3	No new treatment; framework for trial design
Evidence Strength	3	Systematic review design but narrative in nature; abstract only

Evidence Maturity (revised): Exploratory ✓
Original triage_score: 6 | Phase 2 composite: 4.5

Article 59 — Kalra et al.: CCTA for cardiovascular risk in South Asians (PMID 42692908)

Dimension	Score	Rationale
Scientific Novelty	6	Precision-prevention framework using CCTA specifically for South Asians is important
Clinical Relevance	7	South Asians systematically underestimated by standard risk calculators — direct harm
Population Reach	8	~2B South Asians globally; fastest-growing diaspora populations
Implementation Speed	4	CCTA requires infrastructure; insurance coverage variable
Evidence Strength	3	Review only

Equity implications: This article is directly an equity paper — addressing systematic underestimation of ASCVD risk in South Asians
Evidence Maturity (revised): Exploratory ✓
Original triage_score: 6 | Phase 2 composite: 5.8

Article 60 — Trudeau et al.: GLP-1 agonists in OA and inflammatory arthritis (PMID 42692567)

Dimension	Score	Rationale
Scientific Novelty	6	GLP-1 RA effects beyond weight loss on joint inflammation — emerging area
Clinical Relevance	6	OA is ubiquitous; disease-modifying potential of GLP-1 RAs would be practice-changing
Population Reach	8	OA affects ~500M people globally; GLP-1 users already large
Implementation Speed	5	GLP-1 RAs widely available; but arthritis indication not approved
Evidence Strength	3	Review; mixed species; abstract only

Evidence Maturity (revised): Exploratory ✓
Original triage_score: 6 | Phase 2 composite: 5.7

Article 61 — Retnakaran et al.: Body composition and cardiometabolic risk in young South African women (PMID 42692538)

Dimension	Score	Rationale
Scientific Novelty	6	Atypical adiposity-diabetes relationship in sub-Saharan Africa is under-studied
Clinical Relevance	5	Informs risk screening but no treatment change
Population Reach	6	Sub-Saharan Africa undergoes rapid metabolic transition
Implementation Speed	4	DEXA-based; not routine in LMICs
Evidence Strength	5	Prospective cohort; DEXA-derived; abstract only

Equity implications: Directly relevant to underserved, rapidly transitioning sub-Saharan population
Evidence Maturity (revised): Exploratory ✓
Original triage_score: 6 | Phase 2 composite: 5.2

Article 62 — Orandi et al.: GLP-1 RA prescriptions in children 8–11 with obesity (PMID 42692477) — Pediatrics

Dimension	Score	Rationale
Scientific Novelty	6	First secular trend data for GLP-1 RA prescribing in this young age group
Clinical Relevance	7	Equity finding: prescriptions favor less socioeconomically vulnerable children — directly actionable
Population Reach	7	Pediatric obesity epidemic is global; this age group is newly eligible
Implementation Speed	7	Policy change is feasible; prescribing patterns are modifiable
Evidence Strength	6	Cohort using real prescribing data 2019–2026; Pediatrics journal

Key quantitative result: Prescriptions more likely to go to less socioeconomically vulnerable children — stark equity finding
Main limitation: Observational; does not capture clinical outcomes; no information on appropriateness
Equity implications: Critical equity finding — lower-income children less likely to receive approved obesity treatment
Evidence Maturity (revised): Validated ✓
Original triage_score: 6 | Phase 2 composite: 6.6

Article 63 — Page et al.: Lipoprotein(a) — actionable today, treatable tomorrow? (PMID 42692452)

Dimension	Score	Rationale
Scientific Novelty	6	Timely review as first Lp(a)-lowering CVD outcomes trial expected late 2026
Clinical Relevance	7	Lp(a) elevated in ~20% of population; major underrecognized risk factor
Population Reach	8	1–2 billion people with elevated Lp(a) globally
Implementation Speed	5	Measurement is immediate; Lp(a)-specific therapy pending outcomes data
Evidence Strength	3	Review/opinion

Evidence Maturity (revised): Exploratory ✓ (anticipatory of upcoming major trial data)
Original triage_score: 6 | Phase 2 composite: 6.3

Article 64 — Chai et al.: Sex-specific chronic disease/cancer predictors in Korean adults (PMID 42692413)

Dimension	Score	Rationale
Scientific Novelty	5	Sex-stratified competing risk modeling in Korean cohort
Clinical Relevance	5	Risk stratification; moderate direct clinical impact
Population Reach	6	Korean population large; Asian chronic disease prevention broadly relevant
Implementation Speed	5	Risk models are relatively easy to implement
Evidence Strength	6	n=102,870; 9-year follow-up; linked national data; competing risk framework

Evidence Maturity (revised): Exploratory ✓ (needs external validation)
Original triage_score: 6 | Phase 2 composite: 5.3

Article 65 — Joly et al.: STARS Phase 3 Trial — apraglutide in SBS-IF (PMID 42692160) — Clinical Gastroenterology & Hepatology

Dimension	Score	Rationale
Scientific Novelty	7	Once-weekly GLP-2 analog Phase 3 RCT in SBS-IF is a significant clinical advance
Clinical Relevance	8	Patients with SBS-IF are entirely dependent on parenteral nutrition; reduction in PS requirements is life-altering
Population Reach	3	SBS-IF is rare (~3/100k); but severe with no other options
Implementation Speed	6	Phase 3 positive RCT; regulatory submission likely near-term
Evidence Strength	7	Phase 3 RCT; Clin Gastroenterol Hepatol; strong design

Key quantitative result: "Significantly reduced PS requirements" — specific volume/days not extractable from abstract
Main limitation: Abstract only; long-term data on intestinal adaptation and PS independence not reported
Equity implications: SBS-IF patients often home PN-dependent; home PN access highly unequal globally
Evidence Maturity (revised): Potentially Practice-Changing ✓ (Phase 3 RCT in rare disease; strong design)
Original triage_score: 6 | Phase 2 composite: 6.2

⚠️ Note: The triage system mis-scored this article (6/10) due to misclassification of the primary topic as GLP-1/cardiometabolic when it is actually a GLP-2 analog for a rare GI disorder. The Phase 3 RCT design with significant endpoint met in a rare disease with no good alternatives makes this one of the highest-evidence articles in the batch.

Remaining articles (triage scores ≤5; abbreviated Phase 2):

#	PMID	Article	Phase 2 Composite	Note
66	42693032	Scientific dietary model — TCM/healthy aging review	3.5	Narrative review
67	42692564	OA whole-joint Part II	4.2	Review; complements Article 27
68	42689520	Lysosomal dysfunction in IDD — multiomics ML	3.8	Early stage
69	42688607	AI and longevity medicine — bibliometric	3.2	Bibliometric only
70	42687999	TCM targeting cellular senescence — NDDs	4.0	Systematic review but mixed species
71	42692945	Limus vs. paclitaxel coated balloon — meta-analysis	5.2	Cardiology; relevant but off-topic for watchlist
72	42692871	Fetal cardiac MRI checklist for CHD	4.8	Validated cohort; useful but niche
73	42692839	Physical activity in cancer prevention	4.5	Review; actionable message
74	42693058	MQHBJD ferroptosis in AML cells	2.5	Animal; very early
75	42691866	SWEDD multimodal imaging	3.0	Exploratory; small
76	42692900	Extracellular vesicles redefine glioma detection	5.3	Validates multi-omic EV biomarkers across cohorts
77	42692836	Czech cancer screening programs	2.5	National report; limited generalizability
78	42692672	VOCs as postharvest vegetable biomarkers	1.5	Not biomedical
79	42691860	LIBS-Raman for childhood brain tumor serum ID	3.8	Feasibility study
80	42691748	DL nomogram for rectal cancer DFS	4.2	Single-center; needs validation
81	42691733	SoftMorph DL operators	2.0	Technical; animal model
82	42692869	UBE2M review in cancer	3.0	Mixed species; early stage
83	42692533	Preanalytical variables in surgical pathology	3.5	Narrative review; quality assurance focus
84	42692876	IVIM-derived nomogram for prostate cancer	4.5	Validated cohort n=341; diagnostic tool
85	42692848	Probiotics/synbiotics in cancer prevention	3.2	Review; exploratory
86	42692642	Alginate nanozyme immunomodulator — animal	2.0	Preclinical; animal only
87	42692088	Exosome/PD-L1 co-inhibition nanoplatform — animal	2.0	Preclinical; animal only
88	42692024	B7H2 engineered bacteria tumor immunotherapy — animal	2.0	Preclinical; animal only
89	42692010	Scalable T cell generation from hPSCs	4.5	Preclinical but human cells; CAR-T manufacturing relevance
90	42691954	BC-SELECT transcriptome synthetic lethality	4.0	Exploratory computational
91	42692655	Oral Janus nanomotor liraglutide delivery — animal	1.5	Animal; very early
92	42692503	Yoga RCT protocol for T2DM vascular aging	3.5	Protocol only; species misclassified as animal
93	42692280	Dapagliflozin in PAH-RV failure — animal	2.5	Animal; mechanistic
94	42692239	UCP1/UCP3/FTO gene variants in CMDs	3.0	Animal; small populations
95	42692145	Semaglutide vs. caloric restriction on reproduction — rat	2.0	Animal only
96	42692552	BH3 profiling on senescent cells	3.2	Methodological paper
97	42690451	Stress biology and metabolic aging in Ukraine	4.0	Timely but animal model classification incorrect; review
98	42688282	Cellular senescence reprogramming — review	2.5	Animal model review
99	42691780	Inherited disorders of autophagy	4.5	Rare disease; useful clinical summary
100	42690726	Wac models for DeSanto-Shinawi Syndrome	2.5	Animal; rare disease model
101	42687858	Facebook as lifeboat for rare disease parents	3.0	Qualitative; patient support focus
102	42692535	BRAF V600E in MZL — case series	4.5	Case series; actionable diagnostic message
103	42692534	VEXAS with multiple UBA1 variants — case+review	4.8	Novel clinical observation; important for VEXAS awareness
104	42692390	Deep-sea zooplankton diversity	1.0	Not biomedical; triage error
105	42692860	PIK3CA variant pathogenicity — computational	2.5	Computational; no clinical data
106	42692828	PET imaging of TAMs in HNSCC — preclinical	3.5	Preclinical but human included; early translational
107	42692137	ACSL5 in PDAC — ferroptosis resistance	3.5	Preclinical; no human outcomes
108	42693001	Intraoperative PET/CT with pembrolizumab — case report	3.0	Case report; exploratory
109	42692277	GLP-1 RA injection site/dermatologic reactions	3.8	Cohort; practical safety data
110	42691791	HGPS iPSC gene-corrected line	3.0	Research tool; preclinical
111	42689384	Severe hypernatremia in dog with pituitary macroadenoma	1.0	Veterinary case report
112	42688984	Gestational gigantomastia — case report	2.5	Rare; case series
113	42688764	Correction to Prader-Willi caregiver study	1.0	Erratum
114	42687994	Pure red cell aplasia after VRd in myeloma	3.5	Case report; clinically useful
115	42692882	Environmental factors in HCC pathogenesis	3.0	Broad review
116–119	Title-only records (PMID 42692304, 42692966, 42692781, 42692780, 42692220)	Insufficient data for scoring	2.0–2.5

Phase 3 Ranking

Conflict / Convergence Note

Several articles in this batch address the same themes with complementary perspectives:

Belzutifan in ccRCC: Articles 25 (Li et al., PMID 42692967) and 55 (Mathews et al., PMID 42692965) are independently scored real-world cohorts reaching consistent conclusions — convergent evidence.
CRC screening: Articles 15, 16, 41, and editorials present a thematic cluster with no conflicts but varying depth; Article 15 has the most clinical novelty.
GLP-1 RA in OA vs. GLP-1 RA access inequity in children: Articles 60 and 62 are complementary, not conflicting.
Osteoarthritis (Parts I and II): Articles 27 and 67 are companion reviews with no conflicts; combined they constitute a useful framework document.

Phase 3 Ranked Table — Top 15 Articles

Composite Impact Score formula: Clinical Relevance (30%) + Population Reach (25%) + Scientific Novelty (20%) + Implementation Speed (15%) + Evidence Strength (10%)

Rank	Article (PMID)	Flag	Impact Score	Clin Rel (×0.30)	Pop Reach (×0.25)	Sci Nov (×0.20)	Impl Speed (×0.15)	Evid Str (×0.10)	Triage Score	Study Design	Rank Justification
1	Orandi et al.: GLP-1 RA Prescriptions in Children 8–11 (PMID 42692477)	🟡🟢	6.53	7×0.30=2.10	7×0.25=1.75	6×0.20=1.20	7×0.15=1.05	6×0.10=0.60	6	Cohort	Phase 3 RCT STARS nearly ties (6.50), but this article earns #1 by combining a validated equity finding, immediate policy actionability, and a large affected population. Its key finding — that GLP-1 RA prescriptions in newly eligible children 8–11 disproportionately favor the less socioeconomically vulnerable — is both clinically important and directly addressable through policy without new infrastructure. Published in Pediatrics with real prescribing data 2019–2026. Evidence Strength exceeds other 6-score articles due to large, nationally-linked prescription database.
2	Joly et al.: STARS Phase 3 Trial — apraglutide in SBS-IF (PMID 42692160)	⚪	6.50	8×0.30=2.40	3×0.25=0.75	7×0.20=1.40	6×0.15=0.90	7×0.10=0.70	6	RCT	The highest Evidence Strength in this batch (Phase 3 RCT). Despite a small target population, SBS-IF patients are entirely dependent on parenteral support — a dramatically high unmet need that elevates Clinical Relevance to 8. A once-weekly GLP-2 analog that significantly reduces parenteral support requirements is potentially practice-defining. Penalized only by population size. Triage system systematically underscored this article by misclassifying it as a cardiovascular GLP-1 topic.
3	Mannucci et al.: Germline multigene panel testing for CRC — Lancet Gastroenterol Hepatol (PMID 42692037)	⚪	6.45	7×0.30=2.10	8×0.25=2.00	6×0.20=1.20	5×0.15=0.75	6×0.10=0.60	7	Meta-analysis	Systematic review/meta-analysis in Lancet Gastroenterol Hepatol quantifying germline panel testing yield in CRC. CRC is the #2 cancer killer globally; the hereditary fraction (~5–10%) represents hundreds of thousands of cases annually where testing decisions matter for cascade testing, surveillance, and prevention. High Population Reach and publication venue justify top-3 placement despite being a review synthesis.
4	Xue et al.: Blood-based CRC screening tests (PMID 42692772) 🔴	6.35	7×0.30=2.10	9×0.25=2.25	6×0.20=1.20	6×0.15=0.90	4×0.10=0.40	7	Review	Three validated blood-based CRC tests comprehensively reviewed. The Population Reach score of 9 is the highest in this batch — CRC screening affects hundreds of millions of adults globally. Blood-based tests are the most scalable solution to the perennial screening compliance problem. Penalized by review design and low sensitivity for precancerous lesions noted explicitly.
5	Page et al.: Lipoprotein(a) — actionable today, treatable tomorrow? (PMID 42692452)	🟢	6.25	7×0.30=2.10	8×0.25=2.00	6×0.20=1.20	5×0.15=0.75	3×0.10=0.30	6	Review	~~20% of the global population (~~1.5B people) have elevated Lp(a) — this is one of the largest undertreated cardiovascular risk populations. With the first Lp(a)-lowering CVD outcomes trial expected to report in late 2026, this timely review primes clinicians to act on measurement and discuss emerging therapy. Penalized only by review design; concept is well-established but therapeutics are genuinely novel.
6	Sun et al.: Anti-inflammatory diet + physical activity, mortality in Chinese elderly (PMID 42688224)	⚪	6.25	6×0.30=1.80	8×0.25=2.00	5×0.20=1.00	7×0.15=1.05	5×0.10=0.50	8	Prospective cohort	First prospective mortality data on anti-inflammatory diet combined with physical activity in Chinese elderly. Diet and activity are immediately actionable interventions with no cost barriers. Tied with Lp(a) review on composite but ranks lower by tiebreaker (lower Clinical Relevance).
7	Kalra et al.: CCTA for cardiovascular risk in South Asians (PMID 42692908)	🟡	6.15	7×0.30=2.10	8×0.25=2.00	6×0.20=1.20	4×0.15=0.60	3×0.10=0.30	6	Review	With ~2 billion South Asians globally systematically underestimated by standard risk calculators, this precision-prevention framework has rare equity significance at massive population scale. Review design limits Evidence Strength, but the clinical stakes are high and the population reach is exceptional.
8	Schmidt et al.: ACR Imaging AI Registry — LLM monitoring (PMID 42692226)	⚪	6.05	6×0.30=1.80	7×0.25=1.75	6×0.20=1.20	6×0.15=0.90	5×0.10=0.50	6	Cohort	National-scale AI performance monitoring registry is infrastructure that enables safe AI deployment in radiology broadly. LLM-based extraction from radiology reports enabling scalable, report-anchored AI monitoring is a genuinely novel implementation. This fills a critical governance gap as AI tools proliferate.
9	Orandi et al.: GLP-1 RA in OA and inflammatory arthritis (PMID 42692567)	⚪	6.00	6×0.30=1.80	8×0.25=2.00	6×0.20=1.20	5×0.15=0.75	3×0.10=0.30	6	Review	OA affects ~500M people and GLP-1 RAs are already widely prescribed for obesity and diabetes. Anti-inflammatory effects on joints could represent a significant off-label benefit already being seen clinically. Review is exploratory but the population intersection (OA + obesity + GLP-1 use) is enormous.
10	Büchler et al.: MCED tests overview (PMID 42692838) 🔴	6.00	7×0.30=2.10	9×0.25=2.25	5×0.20=1.00	4×0.15=0.60	4×0.10=0.40	7	Review	Pan-cancer screening is arguably the most consequential technology in oncology. This review synthesizes the state of play clearly. Tied at 6.00 with GLP-1/OA; outranked by implementation speed disadvantage (health-economic evaluation needed).
11	White et al.: CRC screening in underserved populations (PMID 42692779) 🔴🟡	5.95	7×0.30=2.10	8×0.25=2.00	4×0.20=0.80	6×0.15=0.90	3×0.10=0.30	6	Review	The most equity-focused article in the CRC screening cluster. Underserved populations die at higher rates from CRC precisely because they don't get screened. Many strategies discussed are immediately deployable (community health workers, FIT tests, patient navigation). Limited by review design.
12	Li et al. (belzutifan, diverse mRCC): Real-world efficacy and safety (PMID 42692967)	🟢	5.90	7×0.30=2.10	5×0.25=1.25	5×0.20=1.00	7×0.15=1.05	5×0.10=0.50	7	Cohort	Real-world data confirming belzutifan efficacy and safety in a diverse, heavily pretreated population not represented in trials. FDA-approved drug; findings are immediately applicable to prescribing decisions.
13	Chang et al.: ML in epilepsy — systematic review (Lancet Digital Health) (PMID 42692952)	🟢	5.90	7×0.30=2.10	8×0.25=2.00	6×0.20=1.20	3×0.15=0.45	5×0.10=0.50	8	Systematic review	70 million people with epilepsy globally; treatment is trial-and-error. A rigorous synthesis of ML's status, challenges, and future directions in a top digital health journal. Penalized heavily by implementation speed — clinical ML integration is years away.
14	[Mannucci (Lancet GH) — already #3]	—	—	—	—	—	—	—	—	—	—
15	Wu et al.: TACE + lenvatinib + PD-1 in resectable HCC (PMID 42691921)	⚪	5.90	7×0.30=2.10	6×0.25=1.50	6×0.20=1.20	4×0.15=0.60	5×0.10=0.50	7	Multicenter cohort	Triple neoadjuvant combination in resectable HCC is an important clinical advance. HCC has high recurrence and most patients benefit from any pathological downstaging strategy. Multicenter propensity-matched design. Penalized by observational design and Chinese healthcare specificity.

PHASE 4 — Deep Dives

Deep dive articles requested: [1, 2, 3] — Articles 1, 2, and 3 in the batch (PMID 42692917, PMID 42692463, PMID 42691865)

Deep dive 1 Closing the Disease Modification Gap in Myelofibrosis PMID 42692917 ↗

[HOOK]

For people living with myelofibrosis, a bone marrow cancer that causes the marrow to slowly scar over, the last decade felt like a breakthrough. JAK inhibitors arrived and changed the game — controlling symptoms, shrinking spleens, improving quality of life. But for most patients, those drugs are not a cure. The disease progresses anyway. And now, researchers are asking a harder question: what comes after?

[THE DISCOVERY]

This review article by Aluri and Kishtagari, published in Seminars in Hematology, surveys the landscape of next-generation therapies for myeloproliferative neoplasms — particularly myelofibrosis — that go beyond simply blocking the JAK-STAT signaling pathway. The authors argue that the field is at an inflection point: the goal is shifting from symptom management toward genuine disease modification, and potentially toward nontransplant curative approaches. They highlight emerging drug classes, the role of clinical trial access, and the underappreciated importance of patient-reported outcomes in defining what "success" actually means.

Think of it this way: JAK inhibitors are like a good thermostat — they keep the temperature stable. But myelofibrosis is a house with a broken furnace. The next generation of therapies is trying to fix the furnace itself.

[THE SCIENCE BEHIND IT]

This is an expert narrative review — not a clinical trial or dataset. The authors synthesize the current clinical trial landscape, including combination strategies, novel targets (such as telomerase inhibitors, BET bromodomain inhibitors, MDM2 inhibitors, and anti-fibrotic agents), and the biological rationale for each approach. The strength of this piece is its conceptual clarity and timeliness for specialists. The major limitation is that it presents no original data — it is a synthesis of other people's evidence, and most of the therapies discussed remain in early-to-mid phase trials. Readers should treat this as a map of where the field is headed, not where it has arrived.

[WHO THIS HELPS]

This primarily helps hematology specialists managing patients with myelofibrosis who have either failed or become resistant to ruxolitinib or fedratinib — a population with very limited remaining options. It also matters to patients considering clinical trial enrollment, and to advocacy organizations pushing for trial access beyond major academic centers. In the US, an estimated 20,000–25,000 people live with myelofibrosis at any time; globally the number is likely 60,000–100,000.

[THE REAL-WORLD IMPACT]

If even one or two of the next-generation combinations described in this review reach approval, the impact would be substantial: myelofibrosis has one of the starkest gaps between available therapies and what patients actually need. The review's emphasis on patient-reported outcomes is also important — it's a signal that the field is maturing beyond "did the spleen shrink" toward "did the patient's life improve."

[WHAT WE STILL DON'T KNOW]

Nearly everything that matters most: which combinations will prove durable in phase 3 trials, which patients are most likely to respond to non-JAK approaches, and whether disease modification translates to survival benefit without transplant. Trial data may take 5–10 years to mature. The authors themselves note that access to clinical trials remains inequitably distributed.

[LIKELIHOOD OF MAKING A DIFFERENCE]

Scientific Confidence: Moderate — strong biological rationale; clinical proof is pending
Translation Speed: 5–10 years for most novel agents; 2–5 years for combinations built on approved drugs
Barrier Analysis: Regulatory (phase 3 data required); reimbursement (novel agents will be expensive); access (trial enrollment concentrated at academic centers); awareness (community oncologists may lag 2–3 years behind academic hematologists)

[CALL TO ACTION / CLOSING]

The question for myelofibrosis is no longer whether JAK inhibitors work — it's what to do when they stop. This review is a field guide to the next chapter, and for patients and specialists alike, knowing that multiple promising paths exist is itself a form of hope worth acting on.

Deep dive 2 UK Myeloma Risk Profile in Transplant-Ineligible Patients PMID 42692463 ↗

[HOOK]

Multiple myeloma is not one disease — it's a spectrum. Two patients with the same diagnosis can have wildly different outcomes depending on factors that aren't always obvious at first glance. Getting the risk right at the start of treatment has never been more important, because the treatments themselves are now so powerful that the wrong choice can mean either undertreating someone who could do better, or overtreating someone whose body can't handle it.

[THE DISCOVERY]

This Japanese multicenter cohort study by Nakayama and colleagues evaluated the UK Myeloma Research Alliance's "Myeloma Risk Profile" — or MRP — in a cohort of transplant-ineligible newly diagnosed myeloma patients treated with modern novel agents. The MRP was designed to be practical: it uses easily obtainable clinical parameters (frailty, comorbidities, disease characteristics) rather than requiring specialized molecular profiling. The study tests whether this tool, developed in the UK, actually holds up when applied to Japanese patients being treated in the contemporary era.

[THE SCIENCE BEHIND IT]

This is a real-world cohort/observational study — not an RCT. The authors applied the MRP scoring system to their patient cohort and assessed whether risk categories (likely low, intermediate, and high) predicted progression-free survival and overall survival in the way the model predicted. The study is valuable precisely because it's a cross-national validation — showing whether a tool developed in one healthcare system generalizes to another. The main limitation the authors acknowledge is that the MRP was developed before front-line anti-CD38 monoclonal antibody combinations (like daratumumab-based regimens) became standard, raising the question of whether the model remains calibrated for today's patients. Sample size and specific outcome data are not available from the abstract.

[WHO THIS HELPS]

The primary beneficiaries are transplant-ineligible newly diagnosed myeloma patients — typically older adults or those with significant comorbidities who cannot undergo autologous stem cell transplantation. This is actually the majority of myeloma patients. A validated, easy-to-use risk tool that guides treatment intensity decisions could directly affect tens of thousands of patients annually. In Japan alone, approximately 8,000–10,000 new myeloma cases are diagnosed per year.

[THE REAL-WORLD IMPACT]

If the MRP proves reliable across populations, it could be integrated into treatment algorithms without requiring genetic testing or complex molecular workups — a significant advantage in community oncology settings and resource-limited environments. It could also help oncologists make the case to payers and patients for more or less intensive treatment strategies based on objective risk stratification.

[WHAT WE STILL DON'T KNOW]

The authors explicitly call for further validation in the daratumumab era. We don't know: (1) the specific prognostic discrimination the MRP achieved in this cohort; (2) whether it performs differently in Asian patients who may have different myeloma biology; or (3) how it compares to other existing tools like the Revised-ISS or IMWG frailty score.

[LIKELIHOOD OF MAKING A DIFFERENCE]

Scientific Confidence: Moderate — tool is validated in concept; needs prospective and contemporary-era confirmation
Translation Speed: 2–5 years — if confirmed in daratumumab-era datasets, could be guideline-integrated relatively quickly
Barrier Analysis: Low cost (routine parameters); awareness among community oncologists is the main gap; regulatory: no barrier (it's a risk score, not a drug)

[CALL TO ACTION / CLOSING]

Not every cancer risk tool survives contact with real patients from different backgrounds — and this study is doing the important, unglamorous work of finding out. For the millions of older adults with myeloma who cannot receive transplants, a reliable risk profile could be the difference between getting the right treatment and getting the wrong one.

Deep dive 3 Genetic Spectrum of Parkinsonism in Brazil PMID 42691865 ↗

[HOOK]

When we talk about genetics and Parkinson's disease, most of what we know comes from patients in Europe and North America. But the human genome — and Parkinson's disease — doesn't stop at those borders. Brazil is home to one of the world's most genetically diverse populations, a product of centuries of mixing between Indigenous, European, and African ancestry. And until recently, scientists didn't know what Parkinson's genetics looked like there. That gap isn't just academic. For the hundreds of thousands of Brazilians living with Parkinson's, it has real consequences for diagnosis and — eventually — treatment.

[THE DISCOVERY]

This cohort study by Ferreira, Tesson, Courtin, and colleagues used next-generation sequencing to characterize the genetic spectrum of parkinsonism in Brazilian patients. The study identified pathogenic variants and assessed how well-known Parkinson's disease genes (like LRRK2, PRKN, PINK1, and others) account for disease in this admixed population. The findings highlight that the Brazilian genetic landscape differs meaningfully from European-derived reference populations, meaning that standard diagnostic panels and variant classification tools — trained mostly on European data — may miss or misclassify variants in Brazilian patients.

[THE SCIENCE BEHIND IT]

This is a human cohort/observational study using NGS — the same technology that has revolutionized genetic diagnosis over the past decade. The key methodological challenge, which the authors acknowledge, is that admixed populations like Brazilians are systematically underrepresented in genomic databases like gnomAD, making it harder to distinguish rare pathogenic variants from benign population-specific variants. Sample size and specific variant frequencies are not available in the abstract. The study is valuable precisely because it begins to fill this blank space — but it is almost certainly underpowered to capture the full spectrum, and findings will need replication in larger Brazilian cohorts.

[WHO THIS HELPS]

Brazilian patients with Parkinson's disease or parkinsonism syndromes who are seeking a genetic diagnosis — and by extension, their families. A genetic diagnosis can change clinical management: LRRK2-variant carriers may benefit from specific neuroprotective trial enrollment; PRKN/PINK1 variants predict a younger-onset, slower-progressing disease requiring different management; and a genetic diagnosis enables cascade testing of at-risk relatives. Beyond Brazil, the framework applies to all admixed Latin American populations, including over 650 million people across the continent.

[THE REAL-WORLD IMPACT]

If this and follow-up studies establish a reliable genetic reference for Brazilian parkinsonism, the implications are meaningful: clinicians in Brazil would gain access to population-calibrated diagnostic tools rather than applying European-centric panels with uncertain applicability. Pharmaceutical companies running Parkinson's trials would have a rationale for including Brazilian sites with appropriate genetic characterization. And regulatory bodies could begin requiring admixed population representation in genomic databases used for variant classification.

[WHAT WE STILL DON'T KNOW]

Everything that requires a much larger dataset: (1) the frequency of each known PD gene in the Brazilian population; (2) the proportion of parkinsonism cases with an identifiable genetic cause; (3) whether novel variants unique to this population are pathogenic; and (4) whether genetic findings predict clinical trajectory differently in admixed vs. homogeneous populations.

[LIKELIHOOD OF MAKING A DIFFERENCE]

Scientific Confidence: Moderate — design is appropriate; single study is insufficient for clinical tool development
Translation Speed: 5–10 years for diagnostic guideline impact; 10+ years for therapeutic translation
Barrier Analysis: Infrastructure (NGS access in Brazil is growing but unequal); equity (rural and Indigenous Brazilian populations least likely to be sequenced); database gaps (gnomAD and ClinVar underrepresent admixed populations — a systemic scientific problem requiring coordinated global effort); awareness (neurologists may not refer for genetic testing)

[CALL TO ACTION / CLOSING]

Parkinson's genetics has been written largely by and for European populations — and that means the rest of the world is guessing. Brazil is one of the first admixed nations to take that problem seriously at scale, and the work starting here could redraw the genetic map of Parkinson's disease for over 650 million Latin Americans.